Posttransplant sCD30 as a biomarker to predict kidney graft outcome

Clinica Chimica Acta

Volumn 413, Issue 17-18, 2012, Pages 1350-1353

  Süsal, Caner ^a   Opelz, Gerhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Graft outcome; Kidney transplantation; SCD30

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CD30 ANTIGEN; CYCLOSPORIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; CD8+ T LYMPHOCYTE; CHRONIC GRAFT REJECTION; CYTOKINE PRODUCTION; DRUG METABOLISM; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENETIC VARIABILITY; GRAFT SURVIVAL; HUMAN; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD30; BIOLOGICAL MARKERS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84862763908     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.10.003     Document Type: Review

References (21)

1. Durkop H., Latza U., Hummel M., Eitelbach F., Seed B., Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992, 68:421-427.
2. Del Prete G. The concept of type-1 and type-2 helper T cells and their cytokines in humans. Int Rev Immunol 1998, 16:427-455.
3. Frezzolini A., Paradisi M., Ruffelli M., Cadoni S., De Pita O. Soluble CD30 in pediatric patients with atopic dermatitis. Allergy 1997, 52:106-109.
4. Saini D., Ramachandran S., Nataraju A., Benshoff N., Liu W., Desai N., et al. Activated effector and memory T cells contribute to circulating sCD30: potential marker for islet allograft rejection. Am J Transplant 2008, 8:1798-1808.
5. Pellegrini P., Berghella A.M., Contasta I., Adorno D. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol 2003, 12:49-61.
6. Süsal C., Pelzl S., Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002, 13:1650-1656.
7. Süsal C., Pelzl S., Opelz G. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 2003, 76:1231-1232.
8. Spiridon C., Hunt J., Mack M., Rosenthal J., Anderson A., Eichhorn E., et al. Evaluation of soluble CD30 as an immunologic marker in heart transplant recipients. Clin Transplant 2008, 22:765-769.
9. Martinez O.M., Villanueva J., Abtahi S., Beatty P.R., Esquivel C.O., Krams S.M. CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation 1998, 65:1240-1247.
10. Gaspal F.M., Kim M.Y., McConnell F.M., Raykundalia C., Bekiaris V., Lane P.J. Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory. J Immunol 2005, 174:3891-3896.
11. Dai Z., Li Q., Wang Y., Gao G., Diggs L.S., Tellides G., et al. CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J Clin Invest 2004, 113:310-317.
12. Velasquez S.Y., Opelz G., Garcia L.F., Alvarez C.M., Süsal C. The source of soluble sCD30 during the alloimmune response. Transplant Int 2011, 24:157.
13. Velasquez S.Y., Paris S., Opelz G., Alvarez C.M., Süsal C. High production of INF-gamma during the alloimmune response is associated with high release of soluble CD30. Transplant Int 2011, 24:159.
14. Pelzl S., Opelz G., Daniel V., Wiesel M., Süsal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003, 75:421-423.
15. Slavcev A., Lácha J., Honsová E., Sajdlová H., Lodererová A., Vitko S., et al. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Transpl Immunol 2005, 14:117-121.
16. Wang D., Wu G.J., Wu W.Z., Yang S.L., Chen J.H., Wang H., et al. Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection. Transpl Immunol 2007, 17:278-282.
17. Kamali K., Abbasi M.A., Farokhi B., Abbasi A., Fallah P., Seifee M.H., et al. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection. Exp Clin Transplant 2009, 7:237-240.
18. Cervelli C., Fontecchio G., Scimitarra M., Azzarone R., Famulari A., Pisani F., et al. Evaluation of serum sCD30 in renal transplantation patients with and without acute rejection. Transplant Proc 2009, 41:1159-1161.
19. Süsal C., Döhler B., Sadeghi M., Salmela K.T., Weimer R., Zeier M., et al. Posttransplant sCD30 as a predictor of kidney graft outcome. Transplantation 2011, 91:1364-1369.
20. Pavlov I., Martins T.B., Delgado J.C. Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing. Clin Vaccine Immunol 2009, 16:1327-1331.
21. Delgado J.C., Pavlov I.Y., Shihab F.S. Post-transplant increased levels of serum sCD30 is a marker for prediction of kidney allograft loss in a 5-year prospective study. Transpl Immunol 2009, 22:1-4.